StreetAlpha.app
Home › Stocks › EYPT

EyePoint, Inc. (EYPT)

Healthcare
$0.23
▼ −11.36%
LAST CLOSE · NOV 20

EyePoint develops DURAVYU, an investigational sustained release eye treatment for serious retinal diseases. It last closed at $0.23 on Nov 20, down 11.36% on the day. The next earnings report for EYPT is expected around Wed, Mar 3, 2027. For the quarter ended Sep 2026, EYPT reported EPS of -$1.07 on revenue of $756,000, with revenue down 21.7% from a year ago. Over its last 8 reports the stock moved an average of 14.3% the session after earnings. Over the last 12 months EYPT insiders bought $72K of stock on the open market and sold $2.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is EYPT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold EYPT.

Key Stats

Last 12 months
Results
Revenue
$2.6M
−93.9% vs a year ago
Net income
−$342.5M
−13281.2% margin
EPS (diluted)
−$3.97
Free cash flow
−$299.1M
−11599.4% margin
Valuation
Market cap
$26.6M
113.8M shares
P/E
–
No P/E while losing money
Price to sales
10.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$83.2M
At Sep 30
Shareholder equity
$108.5M
Shares outstanding
113.8M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $36.9M$36.9MFY2021FY2022: $41.4M$41.4MFY2022FY2023: $46.0M$46.0MFY2023FY2024: $43.3M$43.3MFY2024FY2025: $31.4M$31.4MFY2025

From EYPT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 3
Estimated date · Time not announced
Reported EPS
-$1.07
Quarter ended Sep 2026
Year ago EPS
-$0.85
Same quarter last year
Revenue
$756,000
−21.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.65Dec '24Mar 2025: -$0.65Mar '25Jun 2025: -$0.85Jun '25Sep 2025: -$0.85Sep '25Dec 2025: -$0.82Dec '25Mar 2026: -$0.99Mar '26Jun 2026: -$1.09Jun '26Sep 2026: -$1.07Sep '26Latest -$1.07
Revenue by quarter
Dec 2024: $11.6MDec '24Mar 2025: $24.5MMar '25Jun 2025: $5.3MJun '25Sep 2025: $966,000Sep '25Dec 2025: $620,000Dec '25Mar 2026: $696,000Mar '26Jun 2026: $507,000Jun '26Sep 2026: $756,000Sep '26Latest $756,000
How EYPT moved after its last 8 reports
Average move the session after a report ±14.3%
Oct 19, 2026Time not announced−85.3%
Aug 5, 2026Time not announced+5.0%
May 6, 2026Time not announced−2.9%
Mar 4, 2026Time not announced−1.8%
Jan 7, 2026Time not announced+3.0%
Oct 14, 2025After the close−10.9%
Aug 6, 2025Time not announced−2.9%
May 7, 2025Time not announced−2.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on EYPTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on EYPT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on EYPT

Technical Analysis

EYPT · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 46% below its 20 day and 718% below its 50 day average. It is 4132% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 17), oversold. The nearest support is the 52 week low at $0.23, and the nearest resistance the Pivot at $0.24.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 47.0%/day
Key levels
$19.1152 week high+8208.7%
$9.91200 day average+4208.7%
$5.97100 day average+2495.7%
$1.9150 day average+730.4%
$0.41Swing high (Nov 10)+78.3%
$0.3420 day average+47.8%
$0.26Pivot R1+13.0%
$0.24Pivot+4.3%
$0.2352 week low+0.0%
$0.23Last close
$0.22Pivot S1−4.3%
Indicators
RSI (14)17.14Oversold below 30Oversold
MACD-0.49Above its signal lineBullish
Stochastic2.6Near the bottom of its rangeOversold
ADX (14)64.7Strong downtrend
Williams %R-96.5Oversold below −80, overbought above −20Oversold
CCI (20)-183.2Oversold below −100, overbought above 100Oversold
Rate of change−34.9%Change over 10 sessionsBearish
ATR (14)$0.11Typical daily range, 47.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for EYPT

What happened before

See how EYPT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow EYPT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How EYPT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for EYPTHow many large options trades hit EYPT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

EYPT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲113 buying vs 96 selling
  • ▲Held by funds +2.8 pts
  • ●Funds holding +0
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1901900.0%
In funds' top 1017−85.7%
Held by funds84.4%81.6%+2.8 pts
New / increased44 / 6925 / 65+25.6%
Reduced / sold out53 / 4360 / 24+14.3%
Put/call ratio0.983.17−69.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EYPT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

EYPT Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$72K2 buys · 2 insiders
Sold$2.0M8 sales · 3 insiders
53% of the selling was under pre-arranged trading plans.
2025-12 sold $1.1M2026-01 sold $728K2026-02 sold $37K2026-03 bought $20K2026-03 sold $44K2026-04 sold $37K2026-06 sold $73K2026-08 bought $52KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 18Karen L. ZaderejDirectorBuy10,600$4.93$52K
Jun 30Ramiro RibeiroChief Medical OfficerSale plan4,875$15.01$73K
Apr 17Ramiro RibeiroChief Medical OfficerSale plan2,437$15.00$37K
Mar 16Jay S. DukerPresident and CEOBuy1,500$13.15$20K
Mar 4Ramiro RibeiroChief Medical OfficerSale plan2,438$17.87$44K
Feb 17Ramiro RibeiroChief Medical OfficerSale plan2,437$15.00$37K
Every insider buy and sale for EYPT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See EYPT insider trades →

From SEC Form 4 filings by EYPT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EYPT is in one of them and how their past EYPT trades turned out.

EYPT in the AI portfolios
Loading…

EYPT News Tone and Price

Loading…

EYPT News & Analysis

All StreetAlpha news →
EYPT in the news

About EyePoint

EyePoint is a biopharmaceutical company based in Watertown, Massachusetts, that develops treatments for serious retinal diseases of the eye. Its lead candidate, DURAVYU, combines the drug vorolanib with the company's Durasert E drug delivery technology, which is designed to release medicine steadily inside the eye over a long period. The company is testing DURAVYU for wet AMD and diabetic macular edema, and the treatment has not been approved by the FDA. Its intended patients are people with these conditions, and the eye doctors who would treat them.

Headquarters
Watertown, MA